PureTech Health (LON:PRTC) Sets New 52-Week Low – Here’s Why

Shares of PureTech Health plc (LON:PRTCGet Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 134.80 ($1.68) and last traded at GBX 136.40 ($1.70), with a volume of 325557 shares changing hands. The stock had previously closed at GBX 138 ($1.72).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 455 ($5.68) price objective on shares of PureTech Health in a research note on Monday, December 16th.

Read Our Latest Stock Report on PRTC

PureTech Health Stock Performance

The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68. The firm’s 50-day moving average price is GBX 156.34 and its two-hundred day moving average price is GBX 159.02. The firm has a market capitalization of £335.19 million, a price-to-earnings ratio of -608.70 and a beta of 1.02.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Read More

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.